Pasithea Therapeutics Includes Esketamine Nasal Spray to Clinical Offerings in U.K.

Nov 23, 2021 By MarketDepth

Biotechnology Headlines Healthcare Investing What's Hot

Cancer Research

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has reported that its subsidiary, Pasithea Clinics has been approved to provide Esketamine Nasal Spray (SPRAVATO) for treatment resistant depression in adults and has begun offering treatment in Knightsbridge, London loation.  Three clinics in the U.K. have been accredited to offer this treatment. 

Different Than Current Sprays

SPAVATO CIII nasal spray works differently than current therapies that are available for major depressive disorder.  It is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate receptor, an ionotropic glutamate receptor. 

“This is an important milestone for our U.K. clinics and their patients. Major Depression is the leading cause of long-term disability worldwide. Current treatments have limited success and up to 30% of patients with depression do not respond to consecutive trials of antidepressant treatment. These patients are considered to have treatment-resistant depression and new treatment options are urgently needed.”

Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics

“Esketamine is safe and effective, especially when combined with ongoing psychiatric support. Due to some risks associated with this drug, patients treated in outpatient settings must be enrolled in a specific program. We are extremely proud to have been accredited to provide this treatment, a reflection of our high standards of care,” said Dr. Yassine Bendiabdallah, Managing Director of Pasithea Clinics in the U.K.